• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960

EXPERIMENTAL MEDICINE IN PSYCHIATRY

BRAXIA SCIENTIFIC TO DISCUSS PSYCHIATRIC TREATMENT DISCOVERY AND DEVELOPMENT WITH OXFORD UNIVERSITY RESEARCHERS AT AIMDAY EXPERIMENTAL MEDICINE IN PSYCHIATRY ON JULY 7, 2021

TORONTO, ONTARIO July 7, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research and development company along with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Academic Industry Meeting Day (AIMday) on “Experimental Medicine in Psychiatry,” hosted by Oxford University on Wednesday, July 7, 2021.

Braxia CEO Dr. Roger McIntyre will engage with Oxford scientists on the question of “How can we advance treatment discovery and development in psychiatry targeting cognition?” They will describe how research will be conducted with ketamine and psychedelics that integrates machine-learning, proof-of-mechanism research and implementation science which will be critical for the impact of any innovative psychedelic on population health.
This AIMday will explore questions posed by companies in the early stages of drug development to address how human models within psychiatric drug development may best be used; the kind of data which would help validate their application and future directions for collaboration.

Participating companies include: Braxia Scientific, Lundbeck, Compass Pathways, P1vital, Circadian Therapeutics, Zogenix, Cyclica, Precision Life, Beckley Psytech, BrainBerry, Braincures, BrainPatch, Psious, Jazz Pharmaceuticals & Ranvier Health. To see the workshop topics they will be leading, click here.

For additional information on the conference please visit: https://bit.ly/3xl4BBf

About Braxia Scientific Corp.

Braxia Scientific, is a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders. The medical solutions company aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. The Company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. Braxia Scientific, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., currently operates multidisciplinary community-based clinics offering rapid-onset treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.

ON BEHALF OF THE BOARD
“Dr. Roger S. McIntyre”
Dr. Roger S. McIntyre
Chairman & CEO

FOR FURTHER INFORMATION PLEASE CONTACT:
Braxia Scientific Corp.
Tel: 416-762-2138
Email: [email protected]
Website: www.braxiascientific.com

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are “forward-looking statements.”

Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression and the potential for ketamine to treat other emerging psychiatric disorders, such as Bipolar Depression. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Psilocybin is currently a Schedule III controlled substance under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the “CDSA”) and it is a criminal offence to possess such substance under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

 Symbols – CSE: BRAX  OTC: BRAXF  FWB: 496